Altmann P, Leutmezer F | ||
---|---|---|
Aktuelle Therapiemöglichkeiten der Multiplen Sklerose // Therapy options of multiple sclerosis Journal für Neurologie, Neurochirurgie und Psychiatrie 2018; 19 (1): 3-13 Volltext (PDF) Summary Abbildungen
Keywords: Immuntherapie, Multiple Sklerose, Sicherheit, Wirksamkeit, efficacy, immunomodulatory therapies, multiple sclerosis, safety Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, encompassing both neuroinflammatory as well as prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently licensed drugs could not satisfactorily halt this process. However, in the last years MS treatment has raised a stage of rapid progress. Several new drugs for relapsing remitting MS (RRMS) with improved efficacy have entered the therapeutic field and several others are on the way. In this review, we will summarize pathophysiological apsects of the disease as well as efficacy, safety and tolerability issues of currently licensed drugs for RRMS. Furthermore, new drugs with positive results from phase III clinical trials in RRMS will be highlighted.
Kurzfassung: Multiple Sklerose (MS) ist eine
Autoimmunerkrankung des zentralen Nervensystems, bei der je nach Krankheitsstadien entzündliche und/oder neurodegenerative Pathomechanismen im Vordergrund stehen. Obwohl seit den 1990er Jahren immunmodulatorische
Therapien zur Behandlung der schubförmigen Multiplen Sklerose (RRMS) zur Verfügung stehen, entwickelt ein signifikanter Anteil aller Patienten trotz dieser Therapie bleibende neurologische Defizite. |